Estimation of Infection Force of Hepatitis C Virus Among Drug Users in France

被引:6
|
作者
Kasereka, Selain [1 ]
Le Strat, Yann [2 ]
Leon, Lucie [2 ]
机构
[1] Univ Kinshasa, Kinshasa, DEM REP CONGO
[2] French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, Ile De France, France
关键词
INJECT DRUGS; PEOPLE; PREVENTION; AUSTRALIA; MORTALITY;
D O I
10.1007/978-3-319-58996-1_15
中图分类号
TM [电工技术]; TN [电子技术、通信技术];
学科分类号
0808 ; 0809 ;
摘要
The spread of diseases is a dynamic and complex phenomenon. In the world, they are due to misery and poverty. To understand epidemiological systems is essential for governments. Since modeling simplifies reality, it is an excellent method. The hepatitis C virus (HCV) infection is common worldwide, and injection drug use remains the major mode of transmission of the disease, especially because of equipment sharing. Consequently, it is crucial to monitor the HCV transmission dynamics over time and to assess the effect of harm reduction measures. The aim of this work is to estimate the force of infection of hepatitis C from two national cross-sectional epidemiological surveys conducted in 2004 and 2011 by the French Institute for Public Health Surveillance and its partners in a drug user population in France. HCV prevalence was estimated according to age and calendar time through fractional polynomials adjusted or not to the HIV serological status and to injected drug users or oral drug users in general. The force of infection was modeled according to an SIS (susceptible-infected-susceptible) compartmental model using ordinary differential equations (ODE) and as a function of the derivative of the prevalence function depending on age, time, HIV serological status, and having injected at least once in their life, from 2000 to 2020. Our model was applied on real and simulated surveys using R and Stata software. The results show that HCV prevalence and the force of infection are linked to age and time, and are very high for drug users who injected at least once in their life and who are simultaneously HCV and HIV infected. Based on this model, we estimated that HCV incidence will continue to decline over the following years. Currently in France, there is no cohort study of the HCV among drug users. The only way to estimate HCV incidence in the French population is to use the only existing two national cross-sectional surveys. Our work provides guidance for researchers to compare several cross-sectional epidemiological surveys among drug users and proposes an alternative method to estimate the force of infection among drug users from cross-sectional surveys in the absence of a cohort.
引用
收藏
页码:319 / 344
页数:26
相关论文
共 50 条
  • [21] Hepatitis C virus infection among injecting drug users: Has harm reduction worked?
    Judd, A
    Hickman, M
    Renton, A
    Stimson, G
    ADDICTION RESEARCH, 1999, 7 (01): : 1 - 6
  • [22] The importance of preventing hepatitis C virus infection among injection drug users in the United States
    Alter, MJ
    Moyer, LA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 : S6 - S10
  • [23] Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion
    Hagan, H
    Thiede, H
    Des Jarlais, DC
    EPIDEMIOLOGY, 2004, 15 (05) : 543 - 549
  • [24] Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy
    Enea Spada
    Giovanni Rezza
    Anna Rosa Garbuglia
    Flavia Lucia Lombardo
    Ornella Zuccaro
    Francesca Menniti Ippolito
    Elisabetta Cupellaro
    Stefania Capone
    Maria Rosaria Capobianchi
    Alfredo Nicosia
    Riccardo Cortese
    Antonella Folgori
    Alfonso Mele
    Journal of Urban Health, 2018, 95 : 99 - 110
  • [25] Hepatitis C Virus Infection and Related Risk Factors among Injection Drug Users in Montenegro
    Bacak, Valerio
    Lausevic, Dragan
    Mugosa, Boban
    Vratnica, Zoran
    Terzic, Natasa
    EUROPEAN ADDICTION RESEARCH, 2013, 19 (02) : 68 - 73
  • [26] Prevalence and incidence of hepatitis C virus infection among young adult injection drug users
    Garfein, RS
    Doherty, MC
    Monterroso, ER
    Thomas, DL
    Nelson, KE
    Vlahov, D
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 18 : S11 - S19
  • [27] GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection
    Boodram, B.
    Hershow, R. C.
    Klinzman, D.
    Stapleton, J. T.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : e153 - e159
  • [28] INFLUENCE OF F PROTEIN ON OUTCOME OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS
    Wang Jie
    Zhang Yun
    Yang Jingjing
    Deng Xiaozhao
    Cao Min
    Yu Rongbin
    Xu Ke
    Wang Haopeng
    PROGRESS ON POST-GENOME TECHNOLOGIES AND MODERN NATURAL PRODUCTS, 2011, 2011, : 415 - 418
  • [29] Acute hepatitis C virus infection in incarcerated injection drug users
    McGovern, Barbara H.
    Wurcel, Alysse
    Kim, Arthur Y.
    zur Wiesch, Julian Schulze
    Bica, Ioana
    Zaman, M. Tauheed
    Timm, Joerg
    Walker, Bruce D.
    Lauer, Georg M.
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1663 - 1670
  • [30] Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users
    Reed, Carrie
    Stuver, Sherri O.
    Tumilty, Sheila
    Nunes, David
    Murray, Jessica E.
    Graham, Camilla S.
    Koziel, Margaret James
    Craven, Donald E.
    Skolnik, Paul R.
    Horsburgh, C. Robert, Jr.
    SUBSTANCE ABUSE, 2008, 29 (01) : 5 - 15